61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Background/Significance

The margin status after a lumpectomy is critical to determine the risk of local recurrence. Current guidelines recommend “no ink on tumor” as adequate negative margins for invasive carcinoma. Several studies report that up to 40% of patients may have positive margins requiring a second operation for excision. As such, controversy exists regarding the intraoperative management of margins, with some groups supporting routine cavity shave margins and others favoring selective margin excision based on examination of the specimen plus interpretation of intraoperative radiographs. We hypothesized that a commercially available tumor marking system used at the time of specimen radiography would help reduce the rate of margin positivity.

Materials and Methods

After Institutional Review Board approval, a retrospective review of a prospectively collected cohort of patients was conducted. We included patients older than 18 years diagnosed with invasive breast cancer undergoing breast conservation therapy. At the completion of the lumpectomy, the specimen margins were labeled using clips from the selected commercial tumor marking system; this was followed by a 2-view radiography to determine if shave margins needed to be obtained. The distance between the margin and the tumor border was recorded using a standard millimeter ruler. The radiograph was interpreted by the lead surgeon and shave margins (selective vs complete) were excised at the discretion of the lead surgeon as well. A control group with similar patient characteristics was composed using the same inclusion criteria. In this group, the commercial tumor marking system was not utilized, and the management of the margins was determined by the lead surgeon. Continuous variables are presented as mean with standard deviation and compared using t-test. Categorical variables are presented as frequencies and percentages and compared using χ2tests or Fisherexact tests, as applicable (Table). Significance level was set at 0.05. Analyses were performed using SAS software (Version 9.4).

Results

One hundred and five patients in the study group were compared with 92 patients in the control group. The mean age in both groups was 63 and 64 years, respectively. In the study group, 39% of the cohort underwent selective shave margin excision, and 7% underwent complete margin excision based on the use of the tumor marking system. The control group had a 42% rate of selective margin excision and a significantly higher rate of complete margin excision of 20%. No margins were excised in 53% of the study group vs 37% on the control group. Final pathology of the study and control groups demonstrated positive margins in 23% and 20%, respectively, with no significant difference between the groups.

Conclusion

The use of the tumor marking system did contribute to decreasing the number of patients requiring either selective or complete margin excision; however, no significant difference was found between the groups regarding the rate of margin positivity among the patients who underwent margin excision with and without the use of the tumor marking system.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content